Organon & Co. — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Organon & Co. (OGN)
CIK: 0001821825
Period of Report: 2021-06-04

Reporting Person: LAZARUS ROCHELLE B (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-04	Phantom Stock	$	A	8772	Acquired		Common Stock (8772)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	460	Direct
Common Stock	175	Indirect

Footnotes

F1: Shares acquired in a pro rata distribution by Merck & Co., Inc. ("Merck") of shares of Organon & Co. ("Organon") in connection with the separation of Organon from Merck (the "Separation").

F2: 1-for-1

F3: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.